Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.
Vilsbøll
Tina
T
Gentofte Hospital, Department of Internal Medicine F, University of Copenhagen, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark. t.vilsboll@dadlnet.dk
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D000069450:Liraglutide
D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1